Metabolic Syndrome

• The metabolic syndrome is a multiplex risk factor for atherosclerotic

cardiovascular disease (ASCVD) and type 2 diabetes.
• It doubles risk for ASCVD and, inpatients without diabetes, increases
risk for type 2 diabetes fivefold.
• The metabolic syndrome occurs commonly throughout the world,
ranging in prevalence from 10% to 40%. The syndrome occurs most
often in populations characterized by excessive nutrient intake and
physical inactivity, but underlying metabolic and genetic
susceptibilities are critical factors as well 

Grundy SM. Metabolic Syndrome Update. Trends in Cardiovascular Medicine. 2016:;29(4): 364-373.
Grundy SM. Metabolic Syndrome Update. Trends in Cardiovascular Medicine. 2016:;29(4): 364-373.
Pharmacological Management of Metabolic Syndrome

• First-line pharmacological are statins for dyslipidemia

• Renin-angiotensin-aldosteron system inhibitors for arterial
hypertension
• Metformin or sodium/glucose cotransporter 2 inhibitors or glucagon-
like peptide 1 receptor agonists (GLP-1RAs) for glucose intolerance
• GLP-1RA liraglutide for achieving body weight and waist
circumference reduction.

Larsen JR, Dima L, Correll CU, Manu P. The Pharmacological Managament of Metabolic Syndrome. Expert Rev Clin Pharmacol. 2018; 11(4): 397-410